CLOs on the Move

Moderna Therapeutics

www.modernatx.com

 
Moderna is a clinical stage pioneer of messenger RNA Therapeutics™, an entirely new in vivo drug technology that produces human proteins, antibodies and entirely novel protein constructs inside patient cells, which are in turn secreted or active intracellularly. This breakthrough platform addresses currently undruggable targets and offers a superior alternative to existing drug modalities for a wide range of diseases and conditions. Moderna is developing and plans to commercialize its innovative mRNA drugs through its own ventures and its strategic relationships with established pharmaceutical and biotech companies. Its current ventures are: Onkaido, focused on oncology, Valera, focused on infectious diseases, ...
  • Number of Employees: 250-1000
  • Annual Revenue: $50-100 Million
  • www.modernatx.com
  • 200 Technology Square
    Cambridge, MA USA 02139
  • Phone: 617.714.6500

Executives

Name Title Contact Details
Jerome Maddox
 Vice President and Associate General Counsel, Commercial Legal and Public Policy Profile
Neal Dahiya
 Senior Vice President and Head of Litigation Profile
Lisa Kinsella
 Associate General Counsel Profile
Jacob Moore
 Intellectual Property Counsel Profile
Megan Williams
 VP, Associate General Counsel, Intellectual Property Profile

Similar Companies

Appleton Area Health Services

Appleton Area Health Services is a Appleton, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Nonlethal Technologies

Nonlethal Technologies, Inc is a Homer City, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Rejuvenate Bio

Rejuvenate Bio is developing novel therapies to treat aging and age-related diseases through innovative targeted gene therapies, is developing treatments to reverse aging and address multiple age-related diseases.

AnaptysBio

AnaptysBio is a privately-held antibody development company focused on novel programs in immuno-oncology and inflammation. The Company`s first-in-class proprietary pipeline includes ANB020, an anti-IL-33 antibody for the treatment of severe adult asthma and peanut allergy, and ANB019, an anti-IL-36 receptor antibody for the treatment of generalized pustular psoriasis. AnaptysBio`s SHM-XEL platform has pioneered the use of in vitro somatic hypermutation for antibody discovery and optimization, which replicates key features of the human immune system and overcomes limitations of prior antibody technologies. AnaptysBio has previously announced partnerships with several biopharmaceutical companies, including Novartis, Gilead, Celgene, Momenta and TESARO.

ThinSpring

ThinSpring is a Bridgewater, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.